TB-500 + AOD-9604 Stack: Safety, Monitoring, and Protocol Guide

What Are TB-500 and AOD-9604, and Why Stack Them?

TB-500 is a synthetic analogue of the 43-amino-acid protein thymosin beta-4. The active sequence is a seven-amino-acid actin-binding fragment, Ac-LKKTETQ-NH2 (residues 17-23). Animal data and in vitro work show it accelerates wound closure, reduces inflammation through down-regulation of NF-kB signaling, and promotes angiogenesis. A 2010 study in the Journal of Molecular Medicine confirmed that thymosin beta-4 promotes endothelial cell migration and tube formation at nanomolar concentrations [1].

AOD-9604 is the C-terminal fragment of human growth hormone spanning residues 176-191. Unlike full-length HGH, it does not bind the GH receptor in a way that stimulates IGF-1 production. Its observed effect is stimulation of lipolysis, partly through beta-3 adrenergic receptor activation in adipose tissue. A phase IIb randomized controlled trial (N=298) published by Heffernan et al. In 2001 found that AOD-9604 at 1 mg/day reduced body weight by 2.6 kg over 12 weeks versus 0.8 kg for placebo, though the effect did not reach statistical significance at that dose [2].

Why Practitioners Consider the Combination

The theoretical appeal of stacking them is that the two peptides act on non-overlapping receptors. TB-500 is primarily concerned with cytoskeletal actin dynamics and inflammatory resolution. AOD-9604 acts on adipose tissue metabolism. Combining them is not expected to produce pharmacokinetic interference based on their different molecular targets, though no study has formally tested this assumption.

Clinicians who work in sports medicine and regenerative contexts sometimes suggest the combination for athletes seeking concurrent tissue-repair support and body composition improvement. The rationale is mechanistically defensible. The clinical evidence for that specific combination, however, is absent.

Regulatory Context

The FDA has not approved TB-500 or AOD-9604 for any human indication. AOD-9604 received FDA GRAS (Generally Recognized As Safe) status as a food ingredient in 2014, but that designation covers oral ingestion at food-level doses, not subcutaneous injection at pharmacological doses [3]. TB-500 has no GRAS designation and no IND on record as of this writing. Both compounds are classified as research chemicals. Prescribers outside a formal IRB-approved research protocol operate in a regulatory grey zone, and patients should be fully informed of that status before use.

Mechanism of Action: How Each Peptide Works

TB-500: Actin Sequestration and Repair Signaling

TB-500 binds G-actin (monomeric actin) with high affinity, sequestering it from polymerization into F-actin (filamentous actin). This shifts the intracellular actin balance in a way that promotes cell migration. A 2004 paper in Nature Cell Biology by Bhatt et al. Identified the actin-sequestering domain of thymosin beta-4 as the core driver of its pro-migratory effects [4]. This mechanism underlies the wound-healing and tissue-repair observations seen in rodent models.

TB-500 also down-regulates NF-kB, a master regulator of inflammatory gene transcription. Animal work published in Cardiovascular Research showed that systemic thymosin beta-4 reduced infarct size by 24% and preserved ejection fraction in rat myocardial infarction models [5]. Whether injectable TB-500 fragment reproduces this fully in humans is not established.

AOD-9604: Lipolysis Without IGF-1 Elevation

AOD-9604 was specifically engineered to retain the lipolytic activity of full-length HGH without the growth-promoting (and potentially oncogenic) IGF-1 axis stimulation. The fragment folds into a helical structure that interacts with beta-3 adrenergic receptors on adipocytes, triggering cyclic AMP-mediated lipolysis [6].

A key point for safety monitoring: because AOD-9604 does not meaningfully stimulate IGF-1, concerns about insulin resistance and acromegalic side effects associated with supraphysiologic HGH do not apply in the same way. A 24-week study in obese subjects found no clinically meaningful change in fasting insulin or HbA1c at doses up to 1 mg/day [2]. Glucose monitoring is still recommended because any compound affecting adipose lipolysis theoretically influences free fatty acid flux and hepatic glucose output.

Evidence Quality: What We Know and What We Don't

This is perhaps the most important section of this article, and it deserves a direct statement: no published human RCT has evaluated the TB-500 plus AOD-9604 combination. The evidence base for each peptide individually is thin, and for the stack it is essentially mechanistic inference plus practitioner case observations.

TB-500 Human Data

Human trial data on injectable TB-500 is limited to a small number of phase I safety studies in cardiac repair and ophthalmic settings. RegeneRx Biopharmaceuticals completed a phase II trial of thymosin beta-4 in chronic neurotrophic corneal epithelial defects (NCT01678573), which demonstrated tolerability but modest efficacy. The full peptide, not the 17-23 fragment specifically marketed as TB-500, was used in that trial [7].

AOD-9604 Human Data

AOD-9604 has more human trial data than TB-500. Metabolic Pharmaceuticals conducted four phase II trials between 1997 and 2004. The largest was a 24-week, multicenter, double-blind RCT (N=536) that found the compound safe and well-tolerated but failed to demonstrate statistically significant weight loss versus placebo at its most effective dose [2]. The drug was not advanced to phase III. These trials used oral and subcutaneous routes; the subcutaneous data is most relevant to current practitioner use.

The Combination Gap

The following framework describes what a clinician must synthesize in the absence of direct combination data. First, confirm the mechanisms do not converge on the same receptor or pathway in a way that creates additive toxicity. Second, check that the pharmacokinetic profiles do not create unpredicted interactions (both peptides have short half-lives of 30-90 minutes and are renally cleared as amino acid fragments, making serious PK interaction unlikely). Third, define safety monitoring that covers both compounds individually. Fourth, set a pre-defined stopping criteria before starting.

Dosing Protocols: Ranges Used in Practice

TB-500 Dosing

TB-500 is typically dosed in a loading phase followed by a maintenance phase. A common practitioner pattern is:

• Loading: 2-5 mg twice per week for 4-6 weeks
• Maintenance: 2-5 mg once per week or biweekly thereafter

Some protocols use higher loading doses of 7-10 mg per week for the first two weeks when the indication is acute musculoskeletal injury. Animal data showing accelerated tendon repair used intraperitoneal doses of approximately 150 mcg/kg in rodents, which translates loosely to 2-4 mg in a 70 kg human using standard allometric scaling, though allometric scaling is an imperfect tool for peptides [1].

AOD-9604 Dosing

AOD-9604 is most commonly dosed at 300-500 mcg subcutaneously once daily, typically in the morning in a fasted state to avoid blunting the lipolytic signal with elevated insulin. Some protocols split the dose to 250 mcg twice daily.

The phase II trials used doses ranging from 0.25 mg to 1 mg per day. The 1 mg/day dose was associated with more adverse events (primarily injection-site reactions) without meaningfully better outcomes, which is why 300-500 mcg is the range most practitioners currently use [2].

Combined Protocol Example

A conservative 8-week combined protocol might look like this. Weeks 1-6: TB-500 5 mg subcutaneous twice weekly plus AOD-9604 300 mcg subcutaneous each morning, fasted. Weeks 7-8: TB-500 reduced to 2 mg once weekly, AOD-9604 continued at 300 mcg. Injection sites should be rotated across abdomen, thigh, and lateral hip to reduce lipodystrophy risk from repeated AOD-9604 injections. Both peptides are administered subcutaneously; they should not be mixed in the same syringe because stability data for that combination does not exist.

Safety Profile and Known Adverse Effects

TB-500 Adverse Effects

Human tolerance data from the RegeneRx ophthalmic and cardiac trials showed TB-500 to be well-tolerated at doses up to 42 mg over 6 months, with the most common adverse events being mild injection-site reactions and transient fatigue [7]. Theoretical oncology concern exists because thymosin beta-4 is upregulated in several tumor types and promotes cell migration, which is a mechanism shared with metastasis. A 2012 review in Journal of Cell Science noted that thymosin beta-4 overexpression has been observed in colorectal, gastric, and breast cancers [8]. Whether exogenous short-course administration at peptide doses promotes tumor growth in humans is unknown. Patients with active malignancy or a recent cancer history should not use TB-500 until that question is better characterized.

AOD-9604 Adverse Effects

The phase II trial data identified the following adverse events at rates greater than placebo: injection-site erythema (11% vs. 5% placebo), headache (9% vs. 6%), and nausea (7% vs. 4%). No serious adverse cardiovascular events were attributed to the drug. IGF-1 levels did not change significantly from baseline in any dosing group, confirming the mechanistic prediction [2]. Repeated injections at the same site produced small areas of lipoatrophy in a subset of participants, which resolved over several months after stopping.

Combination-Specific Considerations

When using both compounds together, the safety concerns are additive, not multiplicative, based on current mechanistic understanding. The primary monitoring priorities are:

• Injection site health (both peptides)
• Blood glucose trends (AOD-9604's lipolytic effect on free fatty acid flux)
• Any signs of inflammatory flare (TB-500's immunomodulatory effects are generally suppressive, but individual variation exists)
• Lipid panel (lipolysis increases circulating free fatty acids, which may transiently affect triglycerides)

Safety Monitoring Protocol

A structured monitoring approach reduces risk and creates a defensible clinical record. The following schedule is grounded in the known pharmacology of each compound and standard-of-care guidance for investigational peptide use from the Endocrine Society's position on off-label hormone-adjacent therapies [9].

Before Starting

Run a complete baseline panel that includes: fasting glucose, HbA1c, fasting insulin, complete metabolic panel (CMP), complete blood count (CBC), lipid panel, IGF-1, and C-reactive protein (CRP). Photograph or document any pre-existing musculoskeletal injuries being targeted by TB-500 to allow objective outcome assessment. If the patient has any personal or family history of cancer, thyroid nodules, or autoimmune disease, a specialist consultation is warranted before starting.

At 4-6 Weeks

Repeat fasting glucose, CMP, and CRP. Inspect injection sites at each visit for signs of lipoatrophy, infection, or fibrosis. Review patient-reported outcomes on pain scores or functional mobility if the indication was musculoskeletal. Adjust dosing if any metabolic parameter has shifted by more than 15% from baseline.

At 8-12 Weeks (End of Cycle)

Full panel repeat including IGF-1, HbA1c, lipid panel, and CBC. A rise in IGF-1 above the age-adjusted reference range would be unexpected with AOD-9604 but would warrant stopping and investigating. Any new tumor marker elevation or unexplained lymphadenopathy should prompt imaging and oncology referral given the theoretical TB-500 tumor-migration concern.

Long-Term Use

Long-term safety data past 24 weeks does not exist for either compound in humans. Cycling off for at least 4 weeks between courses is a conservative and reasonable approach. There is no evidence that receptor down-regulation occurs with TB-500, but the absence of evidence is not evidence of absence in this context.

Drug Interactions and Contraindications

Neither TB-500 nor AOD-9604 has been systematically studied for drug-drug interactions in humans. Based on mechanism:

TB-500's anti-inflammatory action may theoretically reduce the apparent efficacy of pro-inflammatory tissue signals that drive natural healing cascades. Concurrent use of NSAIDs or corticosteroids alongside TB-500 has no studied interaction but could mask or alter the inflammatory phase of healing in unpredictable ways [10].

AOD-9604 could theoretically potentiate the glucose-lowering effect of insulin or sulfonylureas by increasing lipolysis and reducing substrate availability for gluconeogenesis. Patients on antidiabetic medications should monitor fasting glucose more frequently. The FDA's guidance on investigational drugs with metabolic effects recommends glucose monitoring at least weekly during the first 4 weeks of any new agent that affects adipose function [11].

Absolute contraindications (based on mechanism and available data):

• Active malignancy or prior malignancy within 5 years
• Pregnancy or breastfeeding
• Age <18 (no pediatric data exists)
• Uncontrolled diabetes (HbA1c >9%)
• Severe renal impairment (eGFR <30 mL/min), as peptide clearance may be impaired

Reconstitution, Storage, and Injection Technique

Both peptides are supplied as lyophilized powder and must be reconstituted with bacteriostatic water. Standard reconstitution for TB-500: add 1-2 mL bacteriostatic water to a 5 mg vial, rotate gently (do not shake), and allow 10 minutes for full dissolution. For AOD-9604: add 1-2 mL bacteriostatic water to a 2 mg or 5 mg vial using the same technique.

Once reconstituted, both peptides should be stored at 2-8 degrees Celsius (standard refrigerator temperature). Reconstituted TB-500 is stable for approximately 14 days refrigerated. AOD-9604 maintains potency for approximately 21 days refrigerated after reconstitution, based on manufacturer stability data, though no published peer-reviewed stability study exists for either compound at these storage conditions.

Injection technique matters for minimizing adverse events. Use a 29-31 gauge, 8-12 mm insulin syringe. Rotate sites with each injection. Pinch subcutaneous fat, insert at 45 degrees, inject slowly, and hold pressure for 10 seconds to reduce bruising. Discard any vial that appears cloudy, discolored, or particulate, as peptide degradation or contamination can occur without obvious visual signs at early stages.

Evidence Summary Table

| Parameter | TB-500 | AOD-9604 | Combined Stack | |---|---|---|---| | Human RCT data | Phase II (ophthalmic, cardiac) | Phase II (obesity, N=536) | None | | FDA approval status | None | None (GRAS oral only) | N/A | | IGF-1 effect | Minimal/none | None confirmed | Not studied | | Primary adverse event | Injection site reaction | Injection site reaction | Additive site reactions | | Cancer risk signal | Theoretical (migration mechanism) | None identified | Unknown | | Glucose effect | None identified | Mild free fatty acid increase | Monitor fasting glucose |